Back to Agenda
Session 3: How Could The JCA Procedure Drive Positive Change? (Roundtable Discussions)
Session Chair(s)
Matias Olsen, MA
Senior Manager, Public Affairs & Policy
European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), Belgium
Valentina Strammiello, MA
Director of Programmes
European Patients' Forum, Belgium
This Session will reflect on the JCA and how can it drive positive change. With a focus on Oncology and ATMPs as the first products in line for EU HTA, participants will be invited to explore though interactive roundtable discussions critical aspects for the implementation of the JCA, such as:
Roundtable 1: How can we ensure the workability of the new system?
Roundtable 2: Evidence generation and assessment methods for Oncology products and ATMPs (which may include OMPs)
Speaker(s)
Key Elements of the JCA Process
Anne Willemsen, MSc
ZIN - National Health Care Institute, Netherlands
Senior Project Manager, Joint Production Co-Lead Partner - Pharmaceuticals
Industry Perspective on Workability
Patrick Hopkinson
Bristol Myers Squibb, United Kingdom
Vice President WW Health Economics & Outcomes Research
Highlights of Oncology Trends Report 2023
Murray Aitken, MBA
IQVIA Institute for Human Data Science, United States
Executive Director
Regulatory Outlook and Challenges in the Areas of Oncology and ATMPs
Francesca Cerreta, PharmD, MPharm, MS
European Medicines Agency, Netherlands
Principal Scientific Officer
Have an account?